about
Searching for the physiological role of glucose-dependent insulinotropic polypeptideHealth care professionals from developing countries report educational benefits after an online diabetes courseFamily and population-based studies of variation within the ghrelin receptor locus in relation to measures of obesity.Patients With Long-QT Syndrome Caused by Impaired hERG-Encoded Kv11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia.An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.KCNQ1 long QT syndrome patients have hyperinsulinemia and symptomatic hypoglycemia.Proteomics reveals the effects of sustained weight loss on the human plasma proteomeTreatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.Liraglutide for Type 2 diabetes and obesity: a 2015 update.Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36.Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study.Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?Large-scale studies of the HphI insulin gene variable-number-of-tandem-repeats polymorphism in relation to Type 2 diabetes mellitus and insulin release.Evidence of an association between the Arg72 allele of the peptide YY and increased risk of type 2 diabetes.Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation.Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity.Major rapid weight loss induces changes in cardiac repolarization.Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.Glucose ingestion causes cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects.Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses.Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation.Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1.Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes.Atrial Natriuretic Peptide in the High Normal Range Is Associated With Lower Prevalence of Insulin Resistance.Genetic analysis of the estrogen-related receptor α and studies of association with obesity and type 2 diabetesVariants in the 5′ region of the neuropeptide Y receptor Y2 gene (NPY2R) are associated with obesity in 5,971 white subjectsWeight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levelsGLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO StudyAssociation between Neuromedin U Gene Variants and Overweight and ObesityA Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture RiskPatients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor AgonistPlasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass SurgeryGain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case reportGreater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressuresGlucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL
P50
Q26749221-32CCD491-7961-4BAF-A6B8-9512CD50B29EQ30854307-293D6939-DF7D-4D0D-B47B-4006477F2C6AQ33559742-0BF5AB8E-3E37-4A80-87E8-8D9E22A67A72Q33625684-1454BAE6-D644-4C23-AC49-AB84FDDA4FE1Q33786150-D5554C9A-64D3-49F6-A1F6-7D25F6743473Q34393350-15716453-BECF-4025-84CB-34400FC8A68DQ34547857-58F0E111-8BF6-49E8-A1A5-201F96E960DAQ34665186-FC6110B5-BE08-433E-BF62-0DDD353BADB7Q35652968-4BBD53AA-1592-4BF0-B756-44EE9E2582C2Q38254745-7F62C22D-167B-4EB4-8C41-3AF10B296A34Q38536672-6894F075-5DE9-4F9F-B470-FC484C3C5C90Q38784664-B7D60B74-3505-4674-81E9-4233C64B9DDAQ39921099-543100D3-6A4E-4E0D-AF84-5C7139E41809Q41181012-C9DB0077-118A-4D21-871A-B52C2F99FAB6Q42730475-53296C00-18DF-4AEA-958F-BF776D20CDF5Q44916004-6E50E876-0353-4292-A743-C4F9F0B6ED23Q46570603-A3511E63-D8B7-4A81-B61F-A5DDADD87699Q46945293-070A2988-CB77-4341-96C6-3131AEF84B57Q47109213-9A51B04C-EE80-446A-87AB-028BCE2E81A8Q47174773-EF2ACE58-5C77-4815-916B-7AAC16C19E20Q47322108-167BD61B-C3DD-4882-9834-86AC3C356896Q50156613-C628D364-ACBC-42EE-B9A1-786E0B9C0E30Q50734342-CFCF8FDC-6878-4D47-90C8-2C99FD810D47Q51245138-16077A4C-9103-4986-8801-E22B829536BEQ51280702-A413A746-09DE-4361-B7BE-9CB5002E3B13Q51331106-7E76919A-8218-4572-9C55-D3DCC9213CE2Q51369780-A4083F93-E133-436A-9B4F-CDF8E3C79B89Q51378108-12994C0B-47FF-41F0-AB79-2FA8E732F0DDQ53799923-6EC0D4A0-95E9-4D01-9ADC-684473122EB2Q57364137-FA22D971-A5F4-4B84-999C-86B0262283B9Q57364152-2602D604-025F-4ED1-9B21-C26D999C5557Q57655866-E0701A27-D19A-444C-B434-2AA609E4FD34Q57655878-7B73E002-B985-495D-A397-F459242516A8Q57731025-C01ABBE7-F157-4ABA-80E7-C302BC7A71CEQ57736751-B3D353C7-7954-4E7F-82FB-F6609D3CFFB0Q60173685-2866BD38-7E5A-4990-8E4F-15FB4E577D83Q63379409-2D0D1546-8724-483F-B494-69C298478E36Q90274136-A70C2444-AF71-42A9-A4D6-654C1A6E86C7Q90503100-F7EEB107-F5A8-4540-BD6B-16AD3325030DQ90569822-67E5079F-0D50-4AE1-BC8C-9984C20A8AD3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Signe Sørensen Torekov
@ast
Signe Sørensen Torekov
@en
Signe Sørensen Torekov
@es
Signe Sørensen Torekov
@fr
Signe Sørensen Torekov
@nl
Signe Sørensen Torekov
@sl
type
label
Signe Sørensen Torekov
@ast
Signe Sørensen Torekov
@en
Signe Sørensen Torekov
@es
Signe Sørensen Torekov
@fr
Signe Sørensen Torekov
@nl
Signe Sørensen Torekov
@sl
altLabel
Torekov SS
@en
prefLabel
Signe Sørensen Torekov
@ast
Signe Sørensen Torekov
@en
Signe Sørensen Torekov
@es
Signe Sørensen Torekov
@fr
Signe Sørensen Torekov
@nl
Signe Sørensen Torekov
@sl
P106
P21
P31
P496
0000-0001-6779-0252